title: Antifibrogenic effects of liposome-encapsulated IFN-alpha2b cream on skin wounds in a fibrotic rabbit ear model.
abstract: This study was conducted to assess the ability of a dermal cream containing liposome-encapsulated interferon- alpha2b (IFN-alpha2b) (LIPO+IFN) to improve hypertrophic scarring in open and reepithelialized dermal wounds in a rabbit fibrotic ear model. Full-thickness skin wounds were made in New Zealand white rabbits, and were either left untreated, treated on day 16 postsurgery (open wound), or treated on day 23 postsurgery (reepithelialized wound) with either LIPO+IFN or liposome alone (LIPO). The conditions of the wounds were monitored until day 35 postsurgery, when hypertrophic scar formation reached its peak. Dry wound weight, scar thickness, hypertrophic index (HI), and tissue cellularity of treated and untreated wounded tissue samples were evaluated as an index for scar formation. The results of this study showed that reepithelialized wounds treated with LIPO+IFN and to a lesser extent with LIPO alone were reduced in thickness, HI, and cellularity compared with untreated control wounds or LIPO+IFN-treated open wounds. Dry wound weight was also reduced but not significantly. The findings of this study suggest that LIPO+IFN is more effective than using LIPO alone in reducing the scar formation in a rabbit fibrotic ear model. Further investigation is required to confirm these results.
authors.affiliation: Department of Surgery, Wound Healing Research Group, University of Alberta, Edmonton, Alberta, Canada T6G 2B7.
authors.forename: Jonathan P
authors.initials: JP
authors.lastname: Lee
authors.forename: Reza B
authors.initials: RB
authors.lastname: Jalili
authors.forename: Edward E
authors.initials: EE
authors.lastname: Tredget
authors.forename: Jack R
authors.initials: JR
authors.lastname: Demare
authors.forename: Aziz
authors.initials: A
authors.lastname: Ghahary
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D017439:Cicatrix, Hypertrophic / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D004423:Ear / Q000293:injuries / Q000473:pathology; D005355:Fibrosis; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008081:Liposomes; D011817:Rabbits; D011994:Recombinant Proteins; D012867:Skin / Q000293:injuries / Q000473:pathology; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D020533:Angiogenesis Inhibitors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008081:Liposomes; D011994:Recombinant Proteins